Based on data from 5260 primary CRC (Fig. 1A), the genetic and immunologic landscape of Chinese CRC patients with KRAS mutation was evaluated, and the clinical significance of TIME was explored and excavated. The gene discussed is KRAS; the disease is colorectal carcinoma.